Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  British Journal of Ophthalmology

• Publication date

  1996-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1136/bjo.80.4.363PMID 8703891PMCID PMC505466
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VASCULAR ENDOTHELIAL GROWTH FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC RETINOPATHY AND OTHER RETINAL DISORDERS

  1995cited by this paper
• Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.

  1995cited by this paper
• INHIBITION OF VEGF PREVENTS OCULAR NEOVASCULARIZATION IN A MONKEY MODEL

  1995cited by this paper
• Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy.

  1994cited by this paper
• Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

  1994cited by this paper
• Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.

  1994cited by this paper
• Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes.

  1994cited by this paper
• Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes.

  1994cited by this paper
• Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells.

  1994cited by this paper
• Ultrastructural features of surgically excised subretinal neovascular membranes in the ocular histoplasmosis syndrome.

  1993cited by this paper
• Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells.

  1993cited by this paper
• Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

  1992cited by this paper
• Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration.

  1992cited by this paper
• Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

  1991cited by this paper
• The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

  1991cited by this paper
• Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome.

  1991cited by this paper
• Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group.

  1990cited by this paper
• Vascular permeability factor, an endothelial cell mitogen related to PDGF.

  1989cited by this paper
• Vascular endothelial growth factor is a secreted angiogenic mitogen.

  1989cited by this paper
• Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells.

  1989cited by this paper
• A human homologue of the yeast GST1 gene codes for a GTP‐binding protein and is expressed in a proliferation‐dependent manner in mammalian cells.

  1989cited by this paper
• A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines.

  1986cited by this paper
• Argon laser photocoagulation for ocular histoplasmosis. Results of a randomized clinical trial.

  1983cited by this paper
• Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

  1983cited by this paper
• Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial.

  1983cited by this paper
• Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial.

  1982cited by this paper
• The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases

  1948cited by this paper

• Microglial regulation of the retinal vasculature in health and during the pathology associated with diabetes.

  2025cites this paper
• Mathematical Models of Topically and Intravitreally Applied Ranibizumab

  2025cites this paper
• A review of the role of EFEMP1 in ophthalmic disease

  2025cites this paper
• Effect of Humanin G (HNG) on Angiogenesis and Neurodegeneration markers in Age-related Macular Degeneration (AMD).

  2023cites this paper
• Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation

  2022cites this paper
• Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy

  2021cites this paper
• Plaidoyer pour une conception fonctionnelle de la pathogénie de la rétinopathie diabétique : Eva Maria Kohner

  2020cites this paper
• Central Role of Oxidative Stress in Age-Related Macular Degeneration: Evidence from a Review of the Molecular Mechanisms and Animal Models

  2020cites this paper
• Progress on ocular siRNA gene‐silencing therapy and drug delivery systems

  2020cites this paper
• Anti-angiogenesis by dual action of R5K peptide conjugated itraconazole nanoparticles

  2020cites this paper
• Drug Targets for Biologics

  2020cites this paper
• Oleanolic Acids Inhibit Vascular Endothelial Growth Factor Receptor 2 Signaling in Endothelial Cells: Implication for Anti-Angiogenic Therapy

  2018cites this paper
• Bevacizumab Injection in Patients with Neovascular Age-Related Macular Degeneration Increases Angiogenic Biomarkers.

  2018cites this paper
• Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases

  2017cites this paper
• Quercetin Mitigates Inflammatory Responses Induced by Vascular Endothelial Growth Factor in Mouse Retinal Photoreceptor Cells through Suppression of Nuclear Factor Kappa B

  2017cites this paper
• Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits

  2017cites this paper
• Celecoxib Down-Regulates the Hypoxia-Induced Expression of HIF-1α and VEGF Through the PI3K/AKT Pathway in Retinal Pigment Epithelial Cells

  2017cites this paper
• Aqueous vascular endothelial growth factor and clinical outcomes correlation after single intravitreal injection of bevacizumab in patients with neovascular age-related macular degeneration

  2017cites this paper
• Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab.

  2016cites this paper
• Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

  2016cites this paper
• Histone Deacetylase Inhibition Restores Retinal Pigment Epithelium Function in Hyperglycemia

  2016cites this paper
• Neovascular Age-Related Macular Degeneration.

  2016cites this paper
• VEGF Receptor-2-Linked PI3K/Calpain/SIRT1 Activation Mediates Retinal Arteriolar Dilations to VEGF and Shear Stress.

  2015cites this paper
• VEGF Splicing and the Role of VEGF Splice Variants: From Physiological-Pathological Conditions to Specific Pre-mRNA Splicing.

  2015cites this paper
• "EVALUACIÓN DE LA DEGENERACIÓN MACULAR TIPO EXUDATIVO RELACIONADA CON LA EDAD, MEDIANTE LA AGUDEZA VISUAL Y ANATOMÍA MACULAR EN PACIENTES TRATADOS CON RANIBIZUMAB INTRAVÍTREO EN EL HOSPITAL CARLOS ANDRADE MARÍN, 2013 - 2014"

  2015cites this paper
• Two Week, OCT-Based follow-up as Guidance for Retreatment with Ranibizumab for CNV Apparently Refractory to Therapy

  2015cites this paper
• Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.

  2014cites this paper
• Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment

  2014cites this paper
• Glycobiology of ocular angiogenesis.

  2014cites this paper
• Amino acid and vascular endothelial growth factor levels in subretinal fluid in rhegmatogenous retinal detachment

  2014cites this paper
• Development of gene therapy for treatment of age‐related macular degeneration

  2014cites this paper
• pharmacotherapeutic approaches for modulating retinal angiogenesis

  2014cites this paper
• Role of genetic factors in the pathogenesis of exudative age-related macular degeneration

  2014cites this paper
• mAbs Targeting Apoptosis, Angiogenesis Inhibitors, and Other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders

  2014cites this paper
• Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis

  2014cites this paper
• Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration

  2013cites this paper
• Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration

  2013influential citation
• Vascular endothelial growth factor and its inhibitor in age-related macular degeneration

  2013cites this paper
• Emerging roles for antiangiogenesis factors in management of ocular disease

  2013cites this paper
• Les thérapies anti-angiogéniques : entre espoir et réalité. Vers l'identification de marqueurs prédictifs et de nouvelles cibles thérapeutiques dans le traitement du cancer du rein

  2013cites this paper
• Classification and Clinical Features of AMD

  2013cites this paper
• Aflibercept ophthalmic solution: drug development and clinical uses

  2013cites this paper
• Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection.

  2013cites this paper
• Concerted inhibition of HIF-1α and -2α expression markedly suppresses angiogenesis in cultured RPE cells

  2013cites this paper
• Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel.

  2012cites this paper
• Vascular endothelial growth factors in retinal and choroidal neovascular diseases

  2012cites this paper
• Safety and Efficacy of Ranibizumab and Bevacizumab for the Treatment of Neovascular Age-related Macular Degeneration

  2012cites this paper
• Treatment of age-related macular degeneration

  2012cites this paper
• Retinal angiomatous proliferation in age–related macular degeneration. 2001.

  2012cites this paper
• Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.

  2012cites this paper
• Wet-amd treatment : a review in the anti-vegf drugs

  2012cites this paper
• Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population

  2012cites this paper
• Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept

  2012cites this paper
• Suggestive association between PLA2G12A single nucleotide polymorphism rs2285714 and response to anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration

  2012cites this paper
• Visual Performance, and it's Response to Intervention, in Subjects with Age-Related Macular Degeneration.

  2012cites this paper
• Neovascular Age-Related Macular Degeneration

  2012cites this paper
• Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.

  2012cites this paper
• Fluorescein angiography, optical coherence tomography, and histopathologic findings in a VEGF165 animal model of retinal angiogenesis

  2012cites this paper
• Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.

  2012cites this paper
• Proteomic analysis of the aqueous humor in age-related macular degeneration (AMD) patients.

  2012cites this paper
• Combined intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.

  2012cites this paper
• Freezing adversely affects measurement of vascular endothelial growth factor levels in human aqueous samples

  2011cites this paper
• Endothelial progenitor cell subpopulation profiling reveals a critical role for endoglin in retinal neovascularization

  2011cites this paper
• Anti-VEGF compounds in the treatment of neovascular age related macular degeneration.

  2011cites this paper
• Validation of Molecular and Genomic Biomarkers of Retinal Drug Efficacy: Use of Ocular Fluid Sampling to Evaluate VEGF

  2011cites this paper
• Lasting Controversy on Ranibizumab and Bevacizumab

  2011cites this paper
• Inflammatory and Angiogenic Protein Detection in the Human Vitreous: Cytometric Bead Assay

  2011cites this paper
• Management of Neovascular AMD

  2011cites this paper
• Age-related macular degeneration: review of current treatments

  2011cites this paper
• Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.

  2011cites this paper
• Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration

  2011cites this paper
• Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab

  2010cites this paper
• Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF

  2010cites this paper
• Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling

  2010cites this paper
• overexpression of VEGF , PDGF and PlGF epithelium cells from light-induced Sorafenib prevents human retinal pigment

  2010cites this paper
• A novel haplotype with the R345W mutation in the EFEMP1 gene associated with autosomal dominant drusen in a Japanese family.

  2010cites this paper
• Inflammatory Mediators and Angiogenic Factors in Choroidal Neovascularization: Pathogenetic Interactions and Therapeutic Implications

  2010cites this paper
• Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration

  2009cites this paper
• Inhibition of choroidal neovascularization in mice by systemic administration of the multikinase inhibitor , sorafenib

  2009cites this paper
• Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits

  2009cites this paper
• [Application of aptamers to medicine: pharmacological profile and results of clinical trials on pegaptanib sodium (Macugen) for age-related macular degeneration].

  2009cites this paper
• アプタマーの医薬品への応用：加齢黄斑変性治療薬ペガプタニブナトリウム（マクジェン®）の薬理学的特徴と臨床成績

  2009cites this paper
• Efficacy of intravitreal bevacizumab (Avastin®) therapy for early and advanced neovascular age‐related macular degeneration

  2009influential citation
• Monitoring ocular drug therapy by analysis of aqueous samples.

  2009cites this paper
• Vascular Endothelial Growth Factors In Eye Diseases Pathophysiology and New Therapeutic Strategies for Retinal and Choroideal Angiogenesis

  2009cites this paper
• Regulation of gene expression for therapy of age related macular degeneration

  2009cites this paper
• Treatment of retinal diseases with VEGF antagonists.

  2009cites this paper
• siRNA therapeutics for age-related macular degeneration: promises and pitfalls

  2009cites this paper
• Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration

  2009cites this paper
• Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy.

  2009cites this paper
• VEGF inhibitors for the treatment of neovascular age-related macular degeneration

  2009cites this paper
• Functional Analysis of Platelet-Activating Factor in the Retinal Pigment Epithelial Cells and Choroidal Endothelial Cells

  2009cites this paper
• Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers

  2008cites this paper
• Transient Bevacizumab (Avastin)-Induced Alterations in Rat Eyes

  2008cites this paper
• Treatment of age-related macular degeneration: focus on ranibizumab

  2008cites this paper
• PPAR-α Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration

  2008cites this paper
• The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration

  2008cites this paper
• Pigment epithelium-derived factor gene Met72Thr polymorphism is associated with increased risk of wet age-related macular degeneration.

  2008cites this paper
• Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration.

  2008cites this paper
• Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes.

  2008cites this paper